amifostine anhydrous has been researched along with Hodgkin Disease in 7 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)." | 2.74 | A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. ( Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009) |
| "Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total body irradiation 2 Gy twice daily on days -8 through -6; cyclophosphamide 6 g/m(2), etoposide 1." | 2.71 | Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. ( Gabriel, DA; Harvey, D; Kirby, SL; Krasnov, C; Moore, DT; Serody, JS; Shea, TC, 2005) |
| "Amifostine can be given safely at a dose of 910 mg/m2 four times in 1 day in combination with HD-CTX." | 2.70 | Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. ( Bosshard, M; Cavalli, F; Egger, HP; Gabutti, L; Ghielmini, M; Kiess, M; Pampallona, S; Sessa, C; Van der Bosch, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigues, NA | 1 |
| Killion, L | 1 |
| Hickey, G | 1 |
| Silver, B | 1 |
| Martin, C | 1 |
| Stevenson, MA | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Phillips, GL | 1 |
| Meisenberg, BR | 1 |
| Reece, DE | 1 |
| Adams, VR | 1 |
| Badros, AZ | 1 |
| Brunner, JL | 1 |
| Fenton, RG | 1 |
| Filicko, J | 1 |
| Grosso, DL | 1 |
| Hale, GA | 1 |
| Howard, DS | 1 |
| Johnson, VP | 1 |
| Kniska, A | 1 |
| Marshall, KW | 1 |
| Mookerjee, B | 1 |
| Nath, R | 1 |
| Rapoport, AP | 1 |
| Sarkodee-Adoo, C | 1 |
| Takebe, N | 1 |
| Vesole, DH | 1 |
| Wagner, JL | 1 |
| Flomenberg, N | 1 |
| Sastry, P | 1 |
| Bhagwat, R | 1 |
| Biswas, G | 1 |
| Khadwal, A | 1 |
| Narayanan, P | 1 |
| Bakshi, A | 1 |
| Parikh, P | 1 |
| Gabriel, DA | 1 |
| Shea, TC | 1 |
| Serody, JS | 1 |
| Moore, DT | 1 |
| Kirby, SL | 1 |
| Harvey, D | 1 |
| Krasnov, C | 1 |
| Ozkaynak, MF | 1 |
| Sahdev, I | 1 |
| Gross, TG | 1 |
| Levine, JE | 1 |
| Cheerva, AC | 1 |
| Richards, MK | 1 |
| Rozans, MK | 1 |
| Shaw, PJ | 1 |
| Kadota, RP | 1 |
| Cagnoni, PJ | 1 |
| Jones, RB | 1 |
| Bearman, SI | 1 |
| Ross, M | 1 |
| Hami, L | 1 |
| Franklin, WA | 1 |
| Capizzi, R | 1 |
| Schein, PS | 1 |
| Shpall, EJ | 1 |
| Ghielmini, M | 1 |
| Van der Bosch, S | 1 |
| Bosshard, M | 1 |
| Pampallona, S | 1 |
| Gabutti, L | 1 |
| Egger, HP | 1 |
| Kiess, M | 1 |
| Cavalli, F | 1 |
| Sessa, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients[NCT00003425] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for amifostine anhydrous and Hodgkin Disease
| Article | Year |
|---|---|
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2009 |
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Hematopoiet | 2004 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cy | 2006 |
Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Topics: Acute Disease; Adolescent; Adult; Amifostine; Cytoprotection; Female; Graft Survival; Hematopoietic | 2005 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2008 |
Use of amifostine in bone marrow purging.
Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cyclophospham | 1996 |
Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents, Alkylating; Bone Marrow; Cyclophosphamid | 2001 |